RxDoctor Payments DataLook up a doctor →

Siddharth Sheth

Internal Medicine · Pittsburgh, PANPI 1982947008

Payments from drug & device makers

$11,039,141in general payments, 2019–2025

Across 275 payments — averaging $40,142 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$10M
  • Beigene, Ltd.$312K
  • Janssen Research & Development, LLC$188K
  • AstraZeneca$184K
  • Astrazeneca UK Limited$100K
  • Exelixis Inc.$96K
  • plus $132K from 8 others

What the payments were for

  • Consulting fees$5,06915%
  • Speaking & faculty fees$19,87560%
  • Travel & lodging$6,34019%
  • Food & beverage$1,9726%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,039,141 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$50,717
Medicare patients
115
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate35$842,787
MekinistTrametinib Dimethyl Sulfoxide46$582,921
TafinlarDabrafenib Mesylate46$486,789
EliquisApixaban12$6,261
Levothyroxine Sodium69$680
Gabapentin11$408
Prochlorperazine Maleate22$257
Oxycodone Hcl19$220
Ondansetron Hcl22$122
Prednisone25$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$5,204$842,78735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →